<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Wagner AD</dc:creator>
  <dc:creator>Grabsch HI</dc:creator>
  <dc:creator>Mauer M</dc:creator>
  <dc:creator>Marreaud S</dc:creator>
  <dc:creator>Caballero C</dc:creator>
  <dc:creator>Thuss-Patience P</dc:creator>
  <dc:creator>Mueller L</dc:creator>
  <dc:creator>Elme A</dc:creator>
  <dc:creator>Moehler MH</dc:creator>
  <dc:creator>Martens U</dc:creator>
  <dc:creator>Kang YK</dc:creator>
  <dc:creator>Rha SY</dc:creator>
  <dc:creator>Cats A</dc:creator>
  <dc:creator>Tokunaga M</dc:creator>
  <dc:creator>Lordick F</dc:creator>
  <dc:date>2019</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">BACKGROUND
10-20% of patients with gastric cancer (GC) have HER2+ tumors. Addition of trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved survival in metastatic, HER2+ GC. When pertuzumab (P) was added to neoadjuvant T and CT, a significant increase in histopathological complete response rate was observed in HER2+ breast cancer. This study aims to investigate the added benefit of using both HER2 targeting drugs (T alone or the combination of T + P), in combination with perioperative CT for localized HER2+ GC.


METHODS
This is a prospective, randomized, open-label, phase II trial. HER2 status from patients with resectable GC (UICC TNM7 tumor stage Ib-III) will be centrally determined. Two hundred and-fifteen patients from 52 sites in 14 countries will be centrally randomized (1:2:2 ratio) to one of the following treatment arms: 1. Standard: CT alone. CT regimens will be FLOT (5-FU, leucovorin, oxaliplatin, taxotere) CapOx (capecitabine, oxaliplatin) or FOLFOX (5-FU, leucovorin, oxaliplatin) according to investigator's choice in Europe, and cisplatin/capecitabine in Asia. 2. Experimental arm 1: CT as in control group, plus T (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks) at day 1, independent of CT chosen for 3 cycles of 3 weeks before and after surgery. 3. Experimental arm 2: CT plus T as in experimental arm 1, plus P (840 mg every 3 weeks) on day 1. Adjuvant treatment with T or T + P will continue for 17 cycles in total. Stratification factors are: histology (intestinal/non-intestinal); region (Asia vs Europe); location (GEJ vs non-GEJ); HER2 immunohistochemistry score (IHC 3+ vs IHC 2+/FISH+) and chemotherapy regimen. Primary objective is to detect an increase in the major pathological response rate from 25 to 45% either with CT plus T alone, or with CT plus the combination of T and P.


DISCUSSION
Depending on the results of the INNOVATION trial, the addition of HER2 targeted treatment with either T or T and P to CT may inform future study designs or become a standard in the perioperative management HER2+ GC.


TRIAL REGISTRATION
This article reports a health care intervention on human participants and was registered on July 10, 2014 under ClinicalTrials.gov identifier: NCT02205047 ; EudraCT: 2014-000722-38.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/259586</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1186/s12885-019-5675-4</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/31126258</dc:relation>
  <dc:source>BMC cancer. - 2019</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Gastric cancer</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Gastro-esophageal junction cancer</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">HER2</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Perioperative chemotherapy</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Pertuzumab</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Trastuzumab</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Adenocarcinoma</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Adult</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Aged</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Aged, 80 and over</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Antibodies, Monoclonal, Humanized</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Antineoplastic Agents</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Antineoplastic Agents, Immunological</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Antineoplastic Combined Chemotherapy Protocols</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Capecitabine</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">Cisplatin</dc:subject>
  <dc:subject xmlns:ns17="xml" ns17:lang="en">Esophageal Neoplasms</dc:subject>
  <dc:subject xmlns:ns18="xml" ns18:lang="en">Esophagogastric Junction</dc:subject>
  <dc:subject xmlns:ns19="xml" ns19:lang="en">Female</dc:subject>
  <dc:subject xmlns:ns20="xml" ns20:lang="en">Fluorouracil</dc:subject>
  <dc:subject xmlns:ns21="xml" ns21:lang="en">Follow-Up Studies</dc:subject>
  <dc:subject xmlns:ns22="xml" ns22:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns23="xml" ns23:lang="en">Male</dc:subject>
  <dc:subject xmlns:ns24="xml" ns24:lang="en">Middle Aged</dc:subject>
  <dc:subject xmlns:ns25="xml" ns25:lang="en">Neoadjuvant Therapy</dc:subject>
  <dc:subject xmlns:ns26="xml" ns26:lang="en">Netherlands</dc:subject>
  <dc:subject xmlns:ns27="xml" ns27:lang="en">Perioperative Period</dc:subject>
  <dc:subject xmlns:ns28="xml" ns28:lang="en">Progression-Free Survival</dc:subject>
  <dc:subject xmlns:ns29="xml" ns29:lang="en">Prospective Studies</dc:subject>
  <dc:subject xmlns:ns30="xml" ns30:lang="en">Receptor, ErbB-2</dc:subject>
  <dc:subject xmlns:ns31="xml" ns31:lang="en">Republic of Korea</dc:subject>
  <dc:subject xmlns:ns32="xml" ns32:lang="en">Stomach Neoplasms</dc:subject>
  <dc:subject xmlns:ns33="xml" ns33:lang="en">Trastuzumab</dc:subject>
  <dc:subject xmlns:ns34="xml" ns34:lang="en">Treatment Outcome</dc:subject>
  <dc:subject xmlns:ns35="xml" ns35:lang="en">Young Adult</dc:subject>
  <dc:title xmlns:ns36="xml" ns36:lang="en">EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
